Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?

Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?

Chris Lange

Fri, September 18, 2026 at 6:06 PM GMT+3 4 min read

Quick Read

• Pfizer's 6.20% yield is real and covered by adjusted EPS guidance of $2.80 to $3.00, though its decade-long annual raise streak has stalled at $0.43.

• Merck raised its quarterly to $0.85 and Bristol-Myers Squibb to $0.63, while Comirnaty and Paxlovid revenue collapses froze Pfizer's payout.

• CEO Albert Bourla pledged Pfizer will maintain and eventually resume growing the dividend once its loss-of-exclusivity period clears.

• Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)

A 6.20% dividend yield in big pharma usually means one of two things: a mispriced income stock or a payout the market has already begun to doubt. Pfizer (NYSE:PFE) trades at $27.67 and the payout's own behavior is the tell.

Raise Pattern: A Streak That Just Went Quiet

Pfizer had lifted its quarterly dividend every year for more than a decade, moving from $0.18 in 2010 to $0.42 across 2024, with the annual bump landing on the January payment. That January step-up happened on schedule at the start of 2025, taking the quarterly to $0.43.

Then the pattern broke. The January 2026 ex-dividend payment came in at $0.43, matching the prior four quarters instead of rising. The May and July 2026 declarations were also $0.43, and the next payment, dated September 1, 2026, holds the same rate. The streak has stalled while the payout remains intact.

Is the Check Funded?

On adjusted earnings, coverage is comfortable. Pfizer reaffirmed 2026 adjusted diluted EPS of $2.80 to $3.00 against a run-rate $1.72 annual payout. Q1 2026 adjusted EPS of $0.75 beat consensus and marked a fifth consecutive quarter above estimates. Cash outflow is real: $2.4 billion in dividends went out in Q1 alone, and $9.8 billion for full-year 2025.

Learn 7 Secret Wealth Tips High Net Worth Investors Use

How do you continue to grow a seven-figure portfolio in retirement? The last thing you want is to run out of money, you want your money to generate lasting income while you enjoy your life.

Learn seven strategies high net worth investors use with new report: The Seven Secrets of High Net Worth Investors from Fisher Investments. Get your guide here (sponsor)

Management has removed the other lever. Pfizer completed no buybacks in 2025 and anticipates none in 2026, even with $3.3 billion of authorization sitting unused. Leverage ended Q2 2026 at 2.7 times. On the August 4, 2026 call, Cecile Guégan, incoming interim CFO, said Pfizer would keep "maintaining, and over the long term, growing the dividend." Chairman and CEO Albert Bourla went further:

"We feel extremely confident that we will, even the most stretched scenarios that we are running, we will be able to maintain our dividend. The dividend will be maintained and eventually after the LOE period will start again growing it."

Peers Aren't Fighting the Same Backdrop

Contrast the freeze with two peers. Merck (NYSE:MRK) lifted its quarterly from $0.81 to $0.85 starting with the December 2025 ex-date. Bristol-Myers Squibb (NYSE:BMY) nudged its payout from $0.62 to $0.63 with the January 2026 ex-date. Both raised. Pfizer did not.

The pressures behind that pause are visible in the mix. Comirnaty fell 59% and Paxlovid fell 62% in Q1 2026, with roughly $1.5 billion in additional generic and biosimilar headwind guided for the year. Offsetting that: launched and acquired products grew 22% operationally, and Vyndamax exclusivity now runs to June 2031.

Growing or Frozen?

The 6.20% yield is real, adjusted-earnings coverage is intact, and management has publicly committed to defending it. For now, income holders are collecting a maintained dividend at the current rate. Until the payout ticks higher again, Pfizer remains a yield story.

A double-digit yield often signals a cut coming, and even a 6% payer with a frozen streak deserves a second look. We laid out the seven warning signs to watch in a free dividend trap guide.

Learn 7 Secret Wealth Tips High Net Worth Investors Use

How do you continue to grow a seven-figure portfolio in retirement? The last thing you want is to run out of money, you want your money to generate lasting income while you enjoy your life.

Learn seven strategies high net worth investors use with new report: The Seven Secrets of High Net Worth Investors from Fisher Investments. Get your guide here (sponsor)

Contact editorial@247wallst.com for any questions or corrections.